Phase II PACE Trial: 2-Year Follow-Up of Ponatinib in CML and Ph+ ALL


Phase II PACE Trial: 2-Year Follow-Up of Ponatinib in CML and Ph+ ALL
Slides from a presentation at ASH 2013 and transcribed comments from recent interviews with Jorge E Cortes, MD (1/24/14) and Hagop M Kantarjian, MD (1/29/14)
Cortes JE et al. Ponatinib in patients (pts) with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) resistant or intolerant to dasatinib or nilotinib, or with the T315I BCR-ABL mutation: 2-year follow-up of the PACE trial. Proc ASH 2013;Abstract 650.

Dr Cortes is Deputy Chairman and Section Chief of AML and CML in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas.

Dr Kantarjian is Chairman and Professor in the Leukemia Department at The University of Texas MD Anderson Cancer Center in Houston, Texas.